Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice.
Identifieur interne : 000A28 ( Main/Exploration ); précédent : 000A27; suivant : 000A29Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice.
Auteurs : Céline Pereira-Gillion [France] ; Mathilde Marot [France] ; Isabelle Griffoul-Espitalier [France] ; Lucia Andras [France] ; Philippe Goupille [France] ; Carine Salliot [France]Source :
- The Journal of rheumatology [ 0315-162X ] ; 2018.
Descripteurs français
- KwdFr :
- Adhésion aux directives (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Antirhumatismaux (administration et posologie), Antirhumatismaux (pharmacologie), Antirhumatismaux (usage thérapeutique), Autorapport (MeSH), Connaissances, attitudes et pratiques en santé (MeSH), Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs), Femelle (MeSH), France (MeSH), Humains (MeSH), Injections sous-cutanées (MeSH), Mise en oeuvre des programmes de santé (MeSH), Mâle (MeSH), Rhumatologues (psychologie), Spondylarthrite (traitement médicamenteux), Sujet âgé (MeSH), Types de pratiques des médecins (MeSH), Études rétrospectives (MeSH).
- MESH :
- administration et posologie : Antirhumatismaux.
- antagonistes et inhibiteurs : Facteur de nécrose tumorale alpha.
- pharmacologie : Antirhumatismaux.
- psychologie : Rhumatologues.
- traitement médicamenteux : Spondylarthrite.
- usage thérapeutique : Antirhumatismaux.
- Adhésion aux directives, Adulte, Adulte d'âge moyen, Autorapport, Connaissances, attitudes et pratiques en santé, Femelle, France, Humains, Injections sous-cutanées, Mise en oeuvre des programmes de santé, Mâle, Sujet âgé, Types de pratiques des médecins, Études rétrospectives.
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), Antirheumatic Agents (administration & dosage), Antirheumatic Agents (pharmacology), Antirheumatic Agents (therapeutic use), Female (MeSH), France (MeSH), Guideline Adherence (MeSH), Health Knowledge, Attitudes, Practice (MeSH), Health Plan Implementation (MeSH), Humans (MeSH), Injections, Subcutaneous (MeSH), Male (MeSH), Middle Aged (MeSH), Practice Patterns, Physicians' (MeSH), Retrospective Studies (MeSH), Rheumatologists (psychology), Self Report (MeSH), Spondylarthritis (drug therapy), Tumor Necrosis Factor-alpha (antagonists & inhibitors).
- MESH :
- chemical , administration & dosage : Antirheumatic Agents.
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , pharmacology : Antirheumatic Agents.
- chemical , therapeutic use : Antirheumatic Agents.
- geographic : France.
- drug therapy : Spondylarthritis.
- psychology : Rheumatologists.
- Adult, Aged, Female, Guideline Adherence, Health Knowledge, Attitudes, Practice, Health Plan Implementation, Humans, Injections, Subcutaneous, Male, Middle Aged, Practice Patterns, Physicians', Retrospective Studies, Self Report.
Abstract
OBJECTIVE
To assess the implementation of European recommendations for use of TNF inhibitors for spondyloarthritis (SpA), rheumatologists' level of knowledge of and adherence to the recommendations, and potential barriers to the application of recommendations.
METHODS
We conducted a retrospective study among 42 rheumatologists who initiated a first subcutaneous TNF inhibitor for SpA in 2013 or 2014. Thirty items from national and international recommendations were separated into 3 domains: indication, pretherapeutic monitoring, and management under TNF inhibitors. A standardized data collection procedure was used to gather data from medical files to assess the application of each recommendation. Questionnaires assessing the knowledge, level of adherence to each recommendation, and potential barriers to their implementation were sent to rheumatologists.
RESULTS
Rheumatologists applied a mean of 60% of items from domains A and B, but less than 50% from domain C items. Recommendations regarding the search for previous infection and the prevention of future infections were the ones most often applied. However, < 60% of rheumatologists assessed cancer and other diseases before TNF inhibitor initiation. More than 95% of rheumatologists knew of the recommendations and had a high level of adherence. Lack of time, difficulties accessing specialized consultations, and lack of flexibility in the recommendations explained rheumatologists' difficulties in applying the recommendations.
CONCLUSION
Despite high levels of knowledge of, and adherence to, recommendations for using TNF inhibitors for SpA, rheumatologists' application was limited because of a lack of human and material resources.
DOI: 10.3899/jrheum.170587
PubMed: 29419472
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice.</title><author><name sortKey="Pereira Gillion, Celine" sort="Pereira Gillion, Celine" uniqKey="Pereira Gillion C" first="Céline" last="Pereira-Gillion">Céline Pereira-Gillion</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Marot, Mathilde" sort="Marot, Mathilde" uniqKey="Marot M" first="Mathilde" last="Marot">Mathilde Marot</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Griffoul Espitalier, Isabelle" sort="Griffoul Espitalier, Isabelle" uniqKey="Griffoul Espitalier I" first="Isabelle" last="Griffoul-Espitalier">Isabelle Griffoul-Espitalier</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Andras, Lucia" sort="Andras, Lucia" uniqKey="Andras L" first="Lucia" last="Andras">Lucia Andras</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Goupille, Philippe" sort="Goupille, Philippe" uniqKey="Goupille P" first="Philippe" last="Goupille">Philippe Goupille</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Salliot, Carine" sort="Salliot, Carine" uniqKey="Salliot C" first="Carine" last="Salliot">Carine Salliot</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France. carine.salliot@chr-orleans.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708. carine.salliot@chr-orleans.fr.</nlm:affiliation><country wicri:rule="url">France</country></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29419472</idno><idno type="pmid">29419472</idno><idno type="doi">10.3899/jrheum.170587</idno><idno type="wicri:Area/Main/Corpus">000920</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000920</idno><idno type="wicri:Area/Main/Curation">000920</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000920</idno><idno type="wicri:Area/Main/Exploration">000920</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice.</title><author><name sortKey="Pereira Gillion, Celine" sort="Pereira Gillion, Celine" uniqKey="Pereira Gillion C" first="Céline" last="Pereira-Gillion">Céline Pereira-Gillion</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Marot, Mathilde" sort="Marot, Mathilde" uniqKey="Marot M" first="Mathilde" last="Marot">Mathilde Marot</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Griffoul Espitalier, Isabelle" sort="Griffoul Espitalier, Isabelle" uniqKey="Griffoul Espitalier I" first="Isabelle" last="Griffoul-Espitalier">Isabelle Griffoul-Espitalier</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Andras, Lucia" sort="Andras, Lucia" uniqKey="Andras L" first="Lucia" last="Andras">Lucia Andras</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Goupille, Philippe" sort="Goupille, Philippe" uniqKey="Goupille P" first="Philippe" last="Goupille">Philippe Goupille</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</nlm:affiliation><wicri:noCountry code="subField">I3MTO Laboratory EA 4708</wicri:noCountry></affiliation></author><author><name sortKey="Salliot, Carine" sort="Salliot, Carine" uniqKey="Salliot C" first="Carine" last="Salliot">Carine Salliot</name><affiliation wicri:level="3"><nlm:affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France. carine.salliot@chr-orleans.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans</wicri:regionArea><placeName><region type="region">Centre-Val de Loire</region><region type="old region">Région Centre</region><settlement type="city">Orléans</settlement></placeName></affiliation><affiliation wicri:level="1"><nlm:affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708. carine.salliot@chr-orleans.fr.</nlm:affiliation><country wicri:rule="url">France</country></affiliation></author></analytic><series><title level="j">The Journal of rheumatology</title><idno type="ISSN">0315-162X</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Antirheumatic Agents (administration & dosage)</term><term>Antirheumatic Agents (pharmacology)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Female (MeSH)</term><term>France (MeSH)</term><term>Guideline Adherence (MeSH)</term><term>Health Knowledge, Attitudes, Practice (MeSH)</term><term>Health Plan Implementation (MeSH)</term><term>Humans (MeSH)</term><term>Injections, Subcutaneous (MeSH)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Practice Patterns, Physicians' (MeSH)</term><term>Retrospective Studies (MeSH)</term><term>Rheumatologists (psychology)</term><term>Self Report (MeSH)</term><term>Spondylarthritis (drug therapy)</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adhésion aux directives (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Antirhumatismaux (administration et posologie)</term><term>Antirhumatismaux (pharmacologie)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Autorapport (MeSH)</term><term>Connaissances, attitudes et pratiques en santé (MeSH)</term><term>Facteur de nécrose tumorale alpha (antagonistes et inhibiteurs)</term><term>Femelle (MeSH)</term><term>France (MeSH)</term><term>Humains (MeSH)</term><term>Injections sous-cutanées (MeSH)</term><term>Mise en oeuvre des programmes de santé (MeSH)</term><term>Mâle (MeSH)</term><term>Rhumatologues (psychologie)</term><term>Spondylarthrite (traitement médicamenteux)</term><term>Sujet âgé (MeSH)</term><term>Types de pratiques des médecins (MeSH)</term><term>Études rétrospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antirheumatic Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Spondylarthritis</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Rhumatologues</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Rheumatologists</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Spondylarthrite</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antirhumatismaux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Guideline Adherence</term><term>Health Knowledge, Attitudes, Practice</term><term>Health Plan Implementation</term><term>Humans</term><term>Injections, Subcutaneous</term><term>Male</term><term>Middle Aged</term><term>Practice Patterns, Physicians'</term><term>Retrospective Studies</term><term>Self Report</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adhésion aux directives</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Autorapport</term><term>Connaissances, attitudes et pratiques en santé</term><term>Femelle</term><term>France</term><term>Humains</term><term>Injections sous-cutanées</term><term>Mise en oeuvre des programmes de santé</term><term>Mâle</term><term>Sujet âgé</term><term>Types de pratiques des médecins</term><term>Études rétrospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To assess the implementation of European recommendations for use of TNF inhibitors for spondyloarthritis (SpA), rheumatologists' level of knowledge of and adherence to the recommendations, and potential barriers to the application of recommendations.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>We conducted a retrospective study among 42 rheumatologists who initiated a first subcutaneous TNF inhibitor for SpA in 2013 or 2014. Thirty items from national and international recommendations were separated into 3 domains: indication, pretherapeutic monitoring, and management under TNF inhibitors. A standardized data collection procedure was used to gather data from medical files to assess the application of each recommendation. Questionnaires assessing the knowledge, level of adherence to each recommendation, and potential barriers to their implementation were sent to rheumatologists.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Rheumatologists applied a mean of 60% of items from domains A and B, but less than 50% from domain C items. Recommendations regarding the search for previous infection and the prevention of future infections were the ones most often applied. However, < 60% of rheumatologists assessed cancer and other diseases before TNF inhibitor initiation. More than 95% of rheumatologists knew of the recommendations and had a high level of adherence. Lack of time, difficulties accessing specialized consultations, and lack of flexibility in the recommendations explained rheumatologists' difficulties in applying the recommendations.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Despite high levels of knowledge of, and adherence to, recommendations for using TNF inhibitors for SpA, rheumatologists' application was limited because of a lack of human and material resources.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29419472</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0315-162X</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>4</Issue><PubDate><Year>2018</Year><Month>04</Month></PubDate></JournalIssue><Title>The Journal of rheumatology</Title><ISOAbbreviation>J Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice.</ArticleTitle><Pagination><MedlinePgn>491-497</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3899/jrheum.170587</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To assess the implementation of European recommendations for use of TNF inhibitors for spondyloarthritis (SpA), rheumatologists' level of knowledge of and adherence to the recommendations, and potential barriers to the application of recommendations.</AbstractText><AbstractText Label="METHODS">We conducted a retrospective study among 42 rheumatologists who initiated a first subcutaneous TNF inhibitor for SpA in 2013 or 2014. Thirty items from national and international recommendations were separated into 3 domains: indication, pretherapeutic monitoring, and management under TNF inhibitors. A standardized data collection procedure was used to gather data from medical files to assess the application of each recommendation. Questionnaires assessing the knowledge, level of adherence to each recommendation, and potential barriers to their implementation were sent to rheumatologists.</AbstractText><AbstractText Label="RESULTS">Rheumatologists applied a mean of 60% of items from domains A and B, but less than 50% from domain C items. Recommendations regarding the search for previous infection and the prevention of future infections were the ones most often applied. However, < 60% of rheumatologists assessed cancer and other diseases before TNF inhibitor initiation. More than 95% of rheumatologists knew of the recommendations and had a high level of adherence. Lack of time, difficulties accessing specialized consultations, and lack of flexibility in the recommendations explained rheumatologists' difficulties in applying the recommendations.</AbstractText><AbstractText Label="CONCLUSION">Despite high levels of knowledge of, and adherence to, recommendations for using TNF inhibitors for SpA, rheumatologists' application was limited because of a lack of human and material resources.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pereira-Gillion</LastName><ForeName>Céline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marot</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffoul-Espitalier</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andras</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goupille</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salliot</LastName><ForeName>Carine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Centre Hospitalier Regional Universitaire (CHRU) de Tours; Université François Rabelais de Tours, Rheumatology Unit, Tours; Centre Hospitalier de Blois, Rheumatology Unit, Blois; Centre Hospitalier Regional d'Orleans, Rheumatology Unit; Université d'Orléans, I3MTO Laboratory EA 4708, Orleans, France. carine.salliot@chr-orleans.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>C. Pereira-Gillion, MD, CHRU de Tours; M. Marot, MD, CHRU de Tours; I. Griffoul-Espitalier, MD, CHRU de Tours; L. Andras, MD, Centre Hospitalier de Blois, Rheumatology Unit; P. Goupille, Professor, CHRU de Tours, and Université François Rabelais de Tours, UMR CNRS 7292, CHRU de Tours; C. Salliot, MD, Centre Hospitalier Regional d'Orleans, Rheumatology Unit, and Université d'Orléans, I3MTO Laboratory EA 4708. carine.salliot@chr-orleans.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>02</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Rheumatol</MedlineTA><NlmUniqueID>7501984</NlmUniqueID><ISSNLinking>0315-162X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="Y">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006284" MajorTopicYN="N">Health Plan Implementation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072140" MajorTopicYN="N">Rheumatologists</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="N">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D025241" MajorTopicYN="N">Spondylarthritis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">RECOMMENDATIONS</Keyword><Keyword MajorTopicYN="Y">RHEUMATOLOGISTS’ PRACTICES</Keyword><Keyword MajorTopicYN="Y">SPONDYLOARTHRITIS</Keyword><Keyword MajorTopicYN="Y">TUMOR NECROSIS FACTOR INHIBITORS</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29419472</ArticleId><ArticleId IdType="pii">jrheum.170587</ArticleId><ArticleId IdType="doi">10.3899/jrheum.170587</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Centre-Val de Loire</li><li>Région Centre</li></region><settlement><li>Orléans</li></settlement></list><tree><country name="France"><region name="Centre-Val de Loire"><name sortKey="Pereira Gillion, Celine" sort="Pereira Gillion, Celine" uniqKey="Pereira Gillion C" first="Céline" last="Pereira-Gillion">Céline Pereira-Gillion</name></region><name sortKey="Andras, Lucia" sort="Andras, Lucia" uniqKey="Andras L" first="Lucia" last="Andras">Lucia Andras</name><name sortKey="Goupille, Philippe" sort="Goupille, Philippe" uniqKey="Goupille P" first="Philippe" last="Goupille">Philippe Goupille</name><name sortKey="Griffoul Espitalier, Isabelle" sort="Griffoul Espitalier, Isabelle" uniqKey="Griffoul Espitalier I" first="Isabelle" last="Griffoul-Espitalier">Isabelle Griffoul-Espitalier</name><name sortKey="Marot, Mathilde" sort="Marot, Mathilde" uniqKey="Marot M" first="Mathilde" last="Marot">Mathilde Marot</name><name sortKey="Salliot, Carine" sort="Salliot, Carine" uniqKey="Salliot C" first="Carine" last="Salliot">Carine Salliot</name><name sortKey="Salliot, Carine" sort="Salliot, Carine" uniqKey="Salliot C" first="Carine" last="Salliot">Carine Salliot</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/AutomedicationFrancoV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000A28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= AutomedicationFrancoV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29419472
|texte= Application of Recommendations Regarding the Use of Subcutaneous Tumor Necrosis Factor Inhibitors in Spondyloarthritis by Rheumatologists in Daily Practice.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29419472" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AutomedicationFrancoV1
| This area was generated with Dilib version V0.6.38. |  |